Savior Lifetec Past Earnings Performance
Past criteria checks 1/6
Savior Lifetec has been growing earnings at an average annual rate of 27.8%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 1.6% per year. Savior Lifetec's return on equity is 0.8%, and it has net margins of 2.9%.
Key information
27.8%
Earnings growth rate
31.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | -1.6% |
| Return on equity | 0.8% |
| Net Margin | 2.9% |
| Next Earnings Update | 03 May 2024 |
Recent past performance updates
Recent updates
Is Savior Lifetec (GTSM:4167) Using Too Much Debt?
Mar 29
Update: Savior Lifetec (GTSM:4167) Stock Gained 35% In The Last Five Years
Feb 22Savior Lifetec Corporation (GTSM:4167) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Jan 25Should You Use Savior Lifetec's (GTSM:4167) Statutory Earnings To Analyse It?
Dec 29Savior Lifetec (GTSM:4167) Seems To Use Debt Quite Sensibly
Dec 03
Revenue & Expenses BreakdownBeta
How Savior Lifetec makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,050 | 30 | 112 | 111 |
| 30 Sep 23 | 986 | -55 | 111 | 110 |
| 30 Jun 23 | 1,047 | 94 | 108 | 114 |
| 31 Mar 23 | 1,180 | 87 | 104 | 116 |
| 31 Dec 22 | 1,266 | 36 | 106 | 119 |
| 30 Sep 22 | 1,347 | 48 | 97 | 131 |
| 30 Jun 22 | 1,378 | -142 | 98 | 152 |
| 31 Mar 22 | 1,545 | -124 | 106 | 165 |
| 31 Dec 21 | 1,744 | 10 | 111 | 167 |
| 30 Sep 21 | 1,976 | 131 | 129 | 179 |
| 30 Jun 21 | 2,026 | 233 | 130 | 170 |
| 31 Mar 21 | 1,904 | 240 | 124 | 174 |
| 31 Dec 20 | 1,827 | 251 | 149 | 179 |
| 30 Sep 20 | 1,636 | 201 | 135 | 180 |
| 30 Jun 20 | 1,548 | 158 | 136 | 191 |
| 31 Mar 20 | 1,450 | 100 | 145 | 189 |
| 31 Dec 19 | 1,319 | -5 | 108 | 188 |
| 30 Sep 19 | 1,194 | -159 | 131 | 186 |
| 30 Jun 19 | 1,113 | -257 | 133 | 158 |
| 31 Mar 19 | 1,122 | -275 | 130 | 148 |
| 31 Dec 18 | 1,105 | -360 | 136 | 143 |
| 30 Sep 18 | 1,173 | -300 | 123 | 142 |
| 30 Jun 18 | 1,302 | -187 | 128 | 171 |
| 31 Mar 18 | 1,432 | -89 | 124 | 195 |
| 31 Dec 17 | 1,618 | 22 | 120 | 216 |
| 30 Sep 17 | 1,781 | 95 | 127 | 229 |
| 30 Jun 17 | 1,801 | 30 | 119 | 236 |
| 31 Mar 17 | 1,704 | -77 | 123 | 237 |
| 31 Dec 16 | 1,532 | -208 | 127 | 243 |
| 30 Sep 16 | 1,303 | -389 | 130 | 247 |
| 30 Jun 16 | 1,185 | -457 | 128 | 256 |
| 31 Mar 16 | 1,127 | -494 | 125 | 254 |
| 31 Dec 15 | 1,121 | -494 | 125 | 256 |
| 30 Sep 15 | 1,195 | -424 | 109 | 257 |
| 30 Jun 15 | 1,119 | -443 | 110 | 253 |
| 31 Mar 15 | 1,081 | -401 | 105 | 257 |
| 31 Dec 14 | 1,019 | -356 | 100 | 257 |
| 30 Sep 14 | 933 | -343 | 93 | 264 |
| 30 Jun 14 | 961 | -245 | 87 | 255 |
| 31 Mar 14 | 968 | -245 | 86 | 232 |
| 31 Dec 13 | 1,001 | -229 | 87 | 208 |
| 30 Sep 13 | 1,000 | -254 | 94 | 168 |
| 30 Jun 13 | 998 | -322 | 99 | 142 |
Quality Earnings: 4167 has a large one-off loss of NT$8.4M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 4167's current net profit margins (2.9%) are lower than last year (2.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4167 has become profitable over the past 5 years, growing earnings by 27.8% per year.
Accelerating Growth: 4167's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4167 had negative earnings growth (-17.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 4167's Return on Equity (0.8%) is considered low.